Skip to main content

Veradermics, Inc

corporate_fare Company Profile

Veradermics, Inc

MANE·NYSE·Life Sciences·CIK 0001827635

We are a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for prevalent aesthetic and dermatological conditions. Our initial focus is on developing better treatments for PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and often result in high rates of treatment failure, patient dissatisfaction, and discontinuation. Patients and healthcare providers frequently cite slow onset of hair growth, inconsistent results, insufficient hair density, tolerability issues related to hormonal, mood, and cardiac side effects, inconvenient administration, and limited FDA-approved options (with no FDA-approved oral options for women) as shortcomings. We are developing VDPHL01 as an oral, non-hormonal treatment for men and women with PHL. VDPHL01 is an oral, ER formulation of minoxidil, a proven hair growth agent. While immediate release (IR) oral minoxidil was originally for resistant hypertension and used off-label for PHL, its release profile was not designed for hair growth, requiring lower doses to reduce cardiac stimulation. VDPHL01 utilizes minoxidil's validated hair growth biology through a novel and proprietary ER formulation designed to maximize total plasma concentrations of minoxidil for hair growth without inducing changes in cardiac activity.

Veradermics, Inc (NYSE:MANE) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 38 items for MANE at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • Veradermics Finalizes $388.8M Public Offering and Private Placement at $100/Share
  • Veradermics Prices Upsized Public Offering and Private Placement to Raise $414.4 Million
  • Veradermics Expands Public Offering to $442 Million Following Positive Clinical Data
  • Veradermics Launches $244M Public Offering and Private Placement at Deep Discount
  • Veradermics Files S-1 for Follow-On Offering to Raise up to $244.9M, Funding Commercialization After Positive Trial Data

Financial Snapshot

Fiscal year ended December 31, 2025
Net Income
-$70M
Diluted EPS
-$111.91
Op. Cash Flow
-$71.6M
Free Cash Flow
-$71.63M
Operating Income
-$72.35M
Cash & Equivalents
$21.77M
Debt / Equity
0.00×
Shares Outstanding
749.76K sh
Source: 10-K · filed 2026-03-30 · accession 0001827635-26-000013
$118.49 -0.86% today
52-week range · as of 2026-11-13 $32 – $156.63
Market cap
$5.04B
Volume
375K (0.6× avg)
3-mo avg 676.2K
Live data · 2026-11-22 12:46 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed MANE - Filings & News (Page 2)

MANE
Apr 30, 2026, 5:28 PM EDT
Filing Type: 424B4
Importance Score:
8
Price at Filing: $99.00
Real-time Price: $118.49 info
Change: +$19.49 (+20%) info
Market Cap: $5.043B info
MANE
Apr 29, 2026, 9:58 PM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $105.48
Real-time Price: $118.49 info
Change: +$13.01 (+12%) info
Market Cap: $5.043B info
MANE
Apr 29, 2026, 9:44 PM EDT
Filing Type: S-1MEF
Importance Score:
8
Price at Filing: $108.50
Real-time Price: $118.49 info
Change: +$9.99 (+9%) info
Market Cap: $5.043B info
MANE
Apr 27, 2026, 5:28 PM EDT
Filing Type: FWP
Importance Score:
8
Price at Filing: $98.00
Real-time Price: $118.49 info
Change: +$20.49 (+21%) info
Market Cap: $5.043B info
MANE
Apr 27, 2026, 5:18 PM EDT
Filing Type: S-1
Importance Score:
8
Price at Filing: $96.30
Real-time Price: $118.49 info
Change: +$22.19 (+23%) info
Market Cap: $5.043B info
MANE
Apr 27, 2026, 5:16 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $96.30
Real-time Price: $118.49 info
Change: +$22.19 (+23%) info
Market Cap: $5.043B info
MANE
Apr 27, 2026, 9:10 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $82.50
Real-time Price: $118.49 info
Change: +$35.99 (+44%) info
Market Cap: $5.043B info
MANE
Mar 30, 2026, 8:44 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $64.00
Real-time Price: $118.49 info
Change: +$54.49 (+85%) info
Market Cap: $5.043B info
MANE
Mar 30, 2026, 7:30 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $64.00
Real-time Price: $118.49 info
Change: +$54.49 (+85%) info
Market Cap: $5.043B info
MANE
Feb 12, 2026, 6:11 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
9
Price at Filing: $44.44
Real-time Price: $118.49 info
Change: +$74.05 (+167%) info
Market Cap: $5.043B info
MANE
Feb 11, 2026, 5:22 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
9
Price at Filing: $43.70
Real-time Price: $118.49 info
Change: +$74.79 (+171%) info
Market Cap: $5.043B info
MANE
Feb 11, 2026, 4:29 PM EST
Filing Type: SCHEDULE 13D
Importance Score:
8
Price at Filing: $43.70
Real-time Price: $118.49 info
Change: +$74.79 (+171%) info
Market Cap: $5.043B info
MANE
Feb 09, 2026, 6:28 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $37.03
Real-time Price: $118.49 info
Change: +$81.46 (+220%) info
Market Cap: $5.043B info
MANE
Feb 05, 2026, 7:04 PM EST
Filing Type: 4
Importance Score:
9
Price at Filing: $35.40
Real-time Price: $118.49 info
Change: +$83.09 (+235%) info
Market Cap: $5.043B info
MANE
Feb 05, 2026, 7:04 PM EST
Filing Type: 4
Importance Score:
9
Price at Filing: $35.40
Real-time Price: $118.49 info
Change: +$83.09 (+235%) info
Market Cap: $5.043B info
MANE
Feb 05, 2026, 7:03 PM EST
Filing Type: 4
Importance Score:
8
Price at Filing: $35.40
Real-time Price: $118.49 info
Change: +$83.09 (+235%) info
Market Cap: $5.043B info
MANE
Feb 05, 2026, 4:21 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $37.16
Real-time Price: $118.49 info
Change: +$81.33 (+219%) info
Market Cap: $5.043B info
MANE
Feb 04, 2026, 5:17 PM EST
Filing Type: 424B4
Importance Score:
9
Price at Filing: $37.15
Real-time Price: $118.49 info
Change: +$81.34 (+219%) info
Market Cap: $5.043B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets